Are there any subsets of patients where you would consider first-line dacomitinib for EGFR mutations positive NSCLC?

Topics: Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer • EGFR+

Are there specific mutations or co-mutations were you would consider use of this agent?

Answer from: Medical Oncologist at Community Practice

I continue to favor osimertinib as front line therapy for patients with EGFR mutation positive NSCLC. A retrospective analysis of response and benefit of osimertinib in some less common EGFR mutations was published, including G719X, L861Q, and S768I. The analysis showed clinical benefit with osimert...

Comments

Medical Oncologist at University of Miami Sylvester Comprehensive Cancer Center
I share the same sentiments with @Karen L. Reckamp...

Related Questions